English | Español

Gilead Sciences Inc. Healthcare Policy PAC
Bree Gonzales | Feb 2, 2022

Molnupiravir is now the last choice for COVID-19: 'The Merck product is only 30% effective'

Trending
+ Pharmaceuticals
Patient Daily | Jun 30, 2025

PhRMA public affairs senior director on 340B program: 'PBMs took $140 billion in rebates and fees, driving up American medicine costs'
+ Pharmaceuticals
Patient Daily | Jul 1, 2025

PhRMA chief public affairs officer on 340B drug pricing: ‘Lowering drug prices for U.S. patients starts by reining in middlemen’
+ Pharmaceuticals
Patient Daily | Jun 25, 2025

Neurosurgeon at the University of California: ‘340B is being exploited for profit, not patient care’